Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products

Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid products
Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss - CNBC
4 stocks to watch on Friday: PM, PFE, MSTR, HIMS
Pfizer says once-a-month weight-loss drug works as it forecasts profit decline
Stocks making the biggest moves premarket: Palantir Technologies, Merck, Pfizer & more - CNBC
159.99BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NYSE
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US7170811035
CUSIP
717081103
Sector
Healthcare
Industry
Drug Manufacturers - General
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
36.93
PEG Ratio
2.72
Book Value
14.95
Dividend Share
1.72
Dividend Yield
6.19%
Earnings Share
0.76
Wall Street Target Price
28.61
EPS Estimate Current Year
2.98
EPS Estimate Next Year
2.90
EPS Estimate Current Quarter
0.6822
EPS Estimate Next Quarter
0.8112
Most Recent Quarter
-
Revenue TTM
63,695,998,976
Gross Profit TTM
47,590,998,016
EBITDA
25,383,000,064
Profit Margin
6.80%
Return On Assets TTM
5.78%
Return On Equity TTM
5.01%
Revenue Per Share TTM
11.193
Qtly Revenue Growth YOY
2.60%
Diluted Eps TTM
0.76
Qtly Earnings Growth YOY
-10.10%
Trailing PE
36.93
Forward PE
9
Price Sales TTM
2.5118
Price Book MRQ
1.878
Enterprise Value Revenue
3
Enterprise Value EBITDA
15
467.65
1.99%58.21
1.68%273.45
1.19%468.10
0.67%166.71
0.47%157.61
0.00%150.67
-1.25%158.02
-0.56%1249.01
-0.49%264.59
-0.12%Curated watchlists where PFE is featured.